Results 201 to 210 of about 108,676 (256)

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

Advanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy, Zoe L. Chau, Sheng‐You Chen, Nanami Fujisawa, John J. Hill, Barnett M. Hsu, Joanne K. Liu, Karol W. Mai, James J. Lai   +8 more
wiley   +1 more source

Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Herpes zoster vaccines may lower the risk of dementia onset. We evaluated new‐onset dementia among US Medicare beneficiaries ≥65 years old following recombinant zoster vaccination (RZV). METHODS We matched one RZV‐exposed to two RZV‐unvaccinated on age, sex, and race/ethnicity. Individuals were ≥65 years old on the RZV dose 2 date
Susan dos Reis, Phuong Tran, Kareshma Mohanty, Alejandro Amill‐Rosario, Abree Johnson, Kathleen Ryan, Hannah Alsdurf, Driss Oraichi, Huifeng Yun   +8 more
wiley   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recombinant bacterial vaccines

Current Opinion in Immunology, 2012
Vaccines are currently available for many infectious diseases caused by several microbes and the prevention of disease and death by vaccination has profoundly improved public health globally. However, vaccines are not yet licensed for use against many other infectious diseases and new or improved vaccines are needed to replace suboptimal vaccines, and ...
Meera, Unnikrishnan, Rino, Rappuoli, Davide, Serruto   +2 more
openaire   +2 more sources

Recombinant vaccines against Leptospirosis

Human Vaccines, 2011
Leptospirosis is an important neglected infectious disease that occurs in urban environments, as well as in rural regions worldwide. Rodents, the principal reservoir hosts of pathogenic Leptospira spp., and other infected animals shed the bacteria in their urine.
Odir A, Dellagostin, André A, Grassmann, Daiane D, Hartwig, Samuel R, Félix, Éverton F, da Silva, Alan J A, McBride   +5 more
openaire   +2 more sources

Recombinant Therapeutic Protein Vaccines

Protein & Peptide Letters, 2013
Recombinant technology has ushered in a new era for the pharmaceutical industry. Protein therapeutics, including plasma-derived products and antibodies obtained from the serum of infected patients, have been successfully adopted and utilized to treat various indications.
Satoshi, Ohtake, Tsutomu, Arakawa
openaire   +2 more sources

Recombinant Vaccines: The Revolution Ahead

2022
The post-vaccination era has boosted constant innovations in the field of medicine and public health and has been instrumental in greatly augmenting the quality of life of human civilization. Ground-breaking scientific innovations in the twentieth and twenty-first centuries have enabled coherent vaccine design and the creation of novel vaccines for a ...
openaire   +2 more sources

Poxvirus Recombinant Vaccines

Annals of the New York Academy of Sciences, 1990
The poxvirus family, subfamily Chordopoxviridae, contains six genera. The basic criteria distinguishing membership in a genus is cross-neutralization and host-range predilection. Members of the genus Orthopoxvirus (vaccinia) and of the genus Avipoxvirus (fowlpox) have been genetically engineered to express genes from heterologous pathogens, thus ...
openaire   +2 more sources

Recombinant Vaccines

2023
Recombinant vaccines employ segments of genetic material from the target virus or bacterium. Unlike traditional vaccines, which often use weakened or inactivated pathogens, recombinant vaccines enable the immune system to recognize and respond to specific components of the pathogen, leading to a targeted and robust immune response.
openaire   +1 more source

Recombinant Adenoviruses as Vaccines

Biologicals, 1995
Over the past 15 years, advances in molecular biology have permitted in vitro and in vivo gene transfer into mammalian cells. Genetically engineered microorganisms are highly promising developments for gene therapy and the future of vaccines. Such vectors constitute genuine tools for high level expression of heterologous genes for both therapeutic and ...
V, Randrianarison-Jewtoukoff, M, Perricaudet   +1 more
openaire   +2 more sources